Patents by Inventor Michael McFarlane

Michael McFarlane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9097588
    Abstract: A UV radiation (UVR) response indicator comprises a first UVB and/or UVA radiation sensitive material which has been modified so as to display an altered characteristic in a delayed manner in response to UVB and/or UVA radiation exposure. The UV indicator is capable of displaying exposure to increased UV radiation over a period of time. The present invention also relates to a method of displaying a relative amount of exposure to UVR by a UV indicator over a period of time. The invention is particularly useful in detecting the level of exposure to sunlight or sunbed radiation.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: August 4, 2015
    Assignee: Intellego Technologies AB
    Inventors: Andrew Mills, Michael McFarlane, Kate McDiarmid, Pauline Grosshans
  • Patent number: 8754240
    Abstract: The present invention relates to a chemical process for the manufacture of a compound of Formula II
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: June 17, 2014
    Assignee: AstraZeneca AB
    Inventors: Euan Alexander Arnott, John Crosby, Mathew Charles Evans, James Gair Ford, Martin Francis Jones, Kevin William Leslie, Ian Michael McFarlane, George Joseph Sependa
  • Publication number: 20130053729
    Abstract: Embodiments relate generally to urine diversion devices for positioning, in use, at least partly within a toilet bowl. The device in some embodiments comprises a body defining a basin and having a collection side and diverting means to divert urine received in the basin toward the collection side; foldable wings coupled to opposed sides of the body and positionable to overlie at least part of respective opposed sides of a toilet seat; and a cradle to hold a urine receptacle and extending from the collection side of the body, the cradle arranged to support the urine receptacle to receive urine diverted toward the collection side.
    Type: Application
    Filed: May 11, 2011
    Publication date: February 28, 2013
    Applicant: FWEE PTY LTD
    Inventors: Darinka Stevic-Wages, Brendan McKeegan, Phillip Michael McFarlane, Paul Charlwood, Luca Abate
  • Publication number: 20120137958
    Abstract: A UV radiation (UVR) response indicator comprises a first UVB and/or UVA radiation sensitive material which has been modified so as to display an altered characteristic in a delayed manner in response to UVB and/or UVA radiation exposure. The UV indicator is capable of displaying exposure to increased UV radiation over a period of time. The present invention also relates to a method of displaying a relative amount of exposure to UVR by a UV indicator over a period of time. The invention is particularly useful in detecting the level of exposure to sunlight or sunbed radiation.
    Type: Application
    Filed: December 18, 2009
    Publication date: June 7, 2012
    Inventors: Andrew Mills, Michael McFarlane, Kate McDiarmid, Pauline Grosshans
  • Publication number: 20110253722
    Abstract: A method for waterproofing a mobile device and a waterproofed mobile device are provided. The method is designed to keep the internal components from elements, such as water, the can damage the mobile device. The method adds a protective coating of a lightweight sealable, heat shrinkable plastic to the internal components of the mobile device and heat shrinks the ends of the of the a lightweight sealable, heat shrinkable plastic together to waterproof the internal components.
    Type: Application
    Filed: April 20, 2010
    Publication date: October 20, 2011
    Applicant: TOMORROW'S INNOVATIONS
    Inventors: Cleveland Morrow, Michael McFarlane
  • Publication number: 20110257395
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline.
    Type: Application
    Filed: November 17, 2010
    Publication date: October 20, 2011
    Applicant: AstraZeneca AB
    Inventors: Euan Alexander Arnott, John Crosby, Matthew Charles Evans, James Gair Ford, Martin Francis Jones, Kevin William Leslie, Ian Michael McFarlane, George Joseph Sependa
  • Patent number: 7851623
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-[(4-fluoro-2-methy-1-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline starting from a compound of Formula IX: wherein R4 is a protecting group; or an intermediate there between, using process steps, reagents and conditions as described.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 14, 2010
    Assignee: AstraZeneca AB
    Inventors: Euan Alexander Arnott, John Crosby, Matthew Charles Evans, James Gair Ford, Martin Francis Jones, Kevin William Leslie, Ian Michael McFarlane, George Joseph Sependa
  • Publication number: 20080221322
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 11, 2008
    Applicant: AstraZeneca AB
    Inventors: Euan Alexander Arnott, John Crosby, Mathew Charles Evans, James Gair Ford, Martin Francis Jones, Kevin William Leslie, Ian Michael McFarlane, George Joseph Sependa
  • Patent number: 6255326
    Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: July 3, 2001
    Assignee: Aventis Pharma Limited
    Inventors: Michael John Ashton, David Charles Cook, Garry Fenton, Susan Jacqueline Hills, Ian Michael McFarlane, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher, Nigel Vicker
  • Patent number: 6096768
    Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: August 1, 2000
    Assignee: Rhone-Poulenc Rorer Limited
    Inventors: Michael John Ashton, David Charles Cook, Garry Fenton, Susan Jacqueline Hills, Ian Michael McFarlane, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher, Nigel Vicker
  • Patent number: 5935978
    Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.
    Type: Grant
    Filed: July 28, 1993
    Date of Patent: August 10, 1999
    Assignee: Rhone-Poulenc Rorer Limited
    Inventors: Garry Fenton, Andrew David Morley, Malcolm Norman Palfreyman, Andrew James Ratcliffe, Brian William Sharp, Sukanthini Thurairatnam, Bernard Yvon Jack Vacher, Michael John Ashton, David Charles Cook, Susan Jacqueline Hills, Ian Michael McFarlane, Nigel Vicker